- Home
- HEQ vs CYBN Comparison
HEQ vs CYBN Comparison
Compare HEQ & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEQ
- CYBN
- Stock Information
- Founded
- HEQ 2011
- CYBN 2019
- Country
- HEQ United States
- CYBN Canada
- Employees
- HEQ N/A
- CYBN N/A
- Industry
- HEQ Investment Managers
- CYBN Pharmaceuticals and Biotechnology
- Sector
- HEQ Finance
- CYBN Health Care
- Exchange
- HEQ Nasdaq
- CYBN Nasdaq
- Market Cap
- HEQ 118.9M
- CYBN 127.3M
- IPO Year
- HEQ N/A
- CYBN N/A
- Fundamental
- Price
- HEQ $10.50
- CYBN $6.62
- Analyst Decision
- HEQ
- CYBN Strong Buy
- Analyst Count
- HEQ 0
- CYBN 4
- Target Price
- HEQ N/A
- CYBN $86.00
- AVG Volume (30 Days)
- HEQ 43.1K
- CYBN 218.9K
- Earning Date
- HEQ 01-01-0001
- CYBN 06-25-2025
- Dividend Yield
- HEQ 9.78%
- CYBN N/A
- EPS Growth
- HEQ N/A
- CYBN N/A
- EPS
- HEQ N/A
- CYBN N/A
- Revenue
- HEQ N/A
- CYBN N/A
- Revenue This Year
- HEQ N/A
- CYBN N/A
- Revenue Next Year
- HEQ N/A
- CYBN N/A
- P/E Ratio
- HEQ N/A
- CYBN N/A
- Revenue Growth
- HEQ N/A
- CYBN N/A
- 52 Week Low
- HEQ $9.08
- CYBN $4.81
- 52 Week High
- HEQ $11.84
- CYBN $14.44
- Technical
- Relative Strength Index (RSI)
- HEQ 64.03
- CYBN 47.85
- Support Level
- HEQ $10.17
- CYBN $6.05
- Resistance Level
- HEQ $10.50
- CYBN $7.29
- Average True Range (ATR)
- HEQ 0.15
- CYBN 0.40
- MACD
- HEQ 0.05
- CYBN 0.02
- Stochastic Oscillator
- HEQ 87.10
- CYBN 45.97
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.